Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

MacLaughlin

Showing results (351-360 of 451) with videos related to

Pageof 46
Sort By:
BMC Cancer|December 7, 2014
Study design and methods for the Breast Cancer and Exercise Trial in Alberta (BETA)Christine M Friedenreich, Sarah MacLaughlin, Heather K Neilson, et al.
Development (Cambridge, England)|December 9, 1997
The paternal allele of the H19 gene is progressively silenced during early mouse development: the acetylation status of histones may be involved in the generation of variegated expression patternsK Svensson, R Mattsson, T C James, et al.
Clinical Pharmacology and Therapeutics|February 1, 1977
Clinical pharmacokinetics of lorazepam. II. Intramuscular injectionD J Greenblatt, T H Joyce, W H Comer, et al.
Journal of Medical Screening|June 13, 2024
Primary human papillomavirus testing by clinician- versus self-collection: Awareness and acceptance among cervical cancer screening-eligible womenKathy L MacLaughlin, Gregory D Jenkins, Jennifer St Sauver, et al.
Journal of Primary Care & Community Health|May 10, 2024
Primary Human Papillomavirus Test Uptake and Cervical Cancer Screening Trends in the Midwest, United StatesKatie M Ehman, Gregory D Jenkins, Jessica A Grimm, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2006
Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivoRafael Pieretti-Vanmarcke, Patricia K Donahoe, Paul Szotek, et al.
Physical Review Letters|October 6, 2000
Observation of two time scales in the ferromagnetic manganite La1-xCaxMnO3, x approximately 0.3R H Heffner, J E Sonier, D E MacLaughlin, et al.
Journal of Biomedical Optics|August 24, 2016
Porphysome nanoparticles for enhanced photothermal therapy in a patient-derived orthotopic pancreas xenograft cancer model: a pilot studyChristina M MacLaughlin, Lili Ding, Cheng Jin, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 8, 2006
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancerRafael Pieretti-Vanmarcke, Patricia K Donahoe, Lisa A Pearsall, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 5, 2002
Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivoDorry L Segev, Yasunori Hoshiya, Makiko Hoshiya, et al.
Pageof 46

Showing results (351-360 of 451) with videos related to

Sort By:
Pageof 46
BMC Cancer|December 7, 2014
Study design and methods for the Breast Cancer and Exercise Trial in Alberta (BETA)Christine M Friedenreich, Sarah MacLaughlin, Heather K Neilson, et al.
Development (Cambridge, England)|December 9, 1997
The paternal allele of the H19 gene is progressively silenced during early mouse development: the acetylation status of histones may be involved in the generation of variegated expression patternsK Svensson, R Mattsson, T C James, et al.
Clinical Pharmacology and Therapeutics|February 1, 1977
Clinical pharmacokinetics of lorazepam. II. Intramuscular injectionD J Greenblatt, T H Joyce, W H Comer, et al.
Journal of Medical Screening|June 13, 2024
Primary human papillomavirus testing by clinician- versus self-collection: Awareness and acceptance among cervical cancer screening-eligible womenKathy L MacLaughlin, Gregory D Jenkins, Jennifer St Sauver, et al.
Journal of Primary Care & Community Health|May 10, 2024
Primary Human Papillomavirus Test Uptake and Cervical Cancer Screening Trends in the Midwest, United StatesKatie M Ehman, Gregory D Jenkins, Jessica A Grimm, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2006
Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivoRafael Pieretti-Vanmarcke, Patricia K Donahoe, Paul Szotek, et al.
Physical Review Letters|October 6, 2000
Observation of two time scales in the ferromagnetic manganite La1-xCaxMnO3, x approximately 0.3R H Heffner, J E Sonier, D E MacLaughlin, et al.
Journal of Biomedical Optics|August 24, 2016
Porphysome nanoparticles for enhanced photothermal therapy in a patient-derived orthotopic pancreas xenograft cancer model: a pilot studyChristina M MacLaughlin, Lili Ding, Cheng Jin, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 8, 2006
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancerRafael Pieretti-Vanmarcke, Patricia K Donahoe, Lisa A Pearsall, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 5, 2002
Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivoDorry L Segev, Yasunori Hoshiya, Makiko Hoshiya, et al.
Pageof 46